RYDAPT DIN 02466236
Health Canada record
| Active ingredient(s) | MIDOSTAURIN 25 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EX10 MIDOSTAURIN |
| Original market date | 08-Sep-2017 |
| Current status date | 08-Sep-2017 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 19563 | 2017-07-21 | New Drug Submission (NDS) |
International API supply for MIDOSTAURIN
9 active FDA Drug Master Files.
Request a quote for RYDAPT